Hair loss

Top Alternative Hair Retailer Wig Studio 1 Launches In-House Brand, PUSH Hair

Retrieved on: 
Thursday, February 1, 2024
Empowerment, Wig, Hair loss, Beauty, Collection, Cosmetics

RIDGEFIELD, Wash., Feb. 1, 2024 /PRNewswire/ -- Top alternative hair retailer, Wig Studio 1, has unveiled its highly anticipated in-house brand, PUSH Hair, marking a significant milestone in the hair solutions industry.

Key Points: 
  • RIDGEFIELD, Wash., Feb. 1, 2024 /PRNewswire/ -- Top alternative hair retailer, Wig Studio 1, has unveiled its highly anticipated in-house brand, PUSH Hair, marking a significant milestone in the hair solutions industry.
  • PUSH Hair is set to redefine the standards of beauty, confidence, and naturalness with its exquisite collection of high-quality wigs and toppers.
  • PUSH Hair is the brainchild of Wig Studio 1, a trusted name known for its dedication to providing individuals facing hair loss with top-tier solutions and service.
  • "We believe that everyone deserves to feel confident and beautiful," says Andrea Carlson, Founder of PUSH Hair.

Frost & Sullivan Co-Published Recombinant Type XVII Collagen Whitepaper with Trautec

Retrieved on: 
Thursday, January 25, 2024
Carbon footprint, Collagen, Research, Basement membrane, Cell adhesion, Shiseido, Tissue, Skin, XVII, Hair loss, Patent, Ageing, B cell, CNY, Growth, Tanning (leather)

Shanghai, China--(Newsfile Corp. - January 25, 2024) -  Frost & Sullivan and Trautec has conducted extensive investigation across the recombinant type xvii collagen and recombinant type XVII collagen industry chain, and co-published Recombinant Type XVII Collagen Whitepaper, which focuses on the recombinant type xvii collagen and recombinant type XVII collagen industry in China as well as new growth opportunities.

Key Points: 
  • Shanghai, China--(Newsfile Corp. - January 25, 2024) -  Frost & Sullivan and Trautec has conducted extensive investigation across the recombinant type xvii collagen and recombinant type XVII collagen industry chain, and co-published Recombinant Type XVII Collagen Whitepaper, which focuses on the recombinant type xvii collagen and recombinant type XVII collagen industry in China as well as new growth opportunities.
  • (To read the Recombinant Type XVII Collagen Whitepaper, go here: https://hub.frost.com/recombinant-type-xvii-collagen/ .)
  • In the process of skin wound repair, type XVII collagen plays a vital role by influencing the migration, proliferation, and differentiation of stem cells.
  • Recombinant Type XVII Collagen Whitepaper highlights the following:
    Recombinant Type XVII Collagen's Biological Functionality(safety, cell adhesion, anti-wrinkle effect, anti-hair loss effect, etc.

Grant Thornton names Alley-Oop Kids as its new Purple Paladin

Retrieved on: 
Tuesday, January 23, 2024
Other Philanthropy, Sports, Family, Social Services, Consumer, General Sports, Other Professional Services, Teens, Legal, Insurance, Children, Small Business, Human Resources, Finance, Consulting, Banking, Accounting, Professional Services, Philanthropy, Fund Raising, Foundation, Dignity, Homelessness, Student, Hope, Museum, Refugee, LPGA, Volunteering, Golf, Hospital, Billie Jean, ESPY Award, Soldier, Hunger, Athlete, Purple, Survivor, Dog, Intellectual, Woman, Sport, Box, Down syndrome, MBC, Book, Veteran, Immunodeficiency, COVID-19, PGA, Locker, Grant Thornton International, Spectrum, Organization, Hair loss, Prescription, Literature, Education, Tourism

In June of 2023, Grant Thornton also worked with another sports-related Purple Paladin, the I GOT THIS Foundation, which promotes golf instruction and playing opportunities for people with intellectual disabilities.

Key Points: 
  • In June of 2023, Grant Thornton also worked with another sports-related Purple Paladin, the I GOT THIS Foundation, which promotes golf instruction and playing opportunities for people with intellectual disabilities.
  • To learn more about Alley-Oop Kids, visit https://www.alleyoopkids.org/
    Alley-Oop Kids joins 17 other 501(c)(3) nonprofits that Grant Thornton previously selected as Purple Paladins.
  • Grant Thornton’s Purple Paladins program derives its name from the word paladin, a champion of a cause.
  • Grant Thornton and its professionals have donated more than $1 million to Purple Paladin nonprofits, and more than 650 Grant Thornton professionals have volunteered their time and skills to support the firm’s Purple Paladins.

CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market to grow by USD 2.23 billion between 2023 and 2028, growth Driven by High target affinity and specificity of CTLA4 inhibitors - Technavio

Retrieved on: 
Friday, January 26, 2024
Bristol Myers Squibb, Cytotoxicity, Research, Incidence, Melanoma, ROW, Biotechnology, AstraZeneca, Ipilimumab, HDAC, Carcinoma, Bone marrow suppression, Growth, BioNTech, Bio-Techne, NSCLC, Combination therapy, Investment, Disease, BMS, USD, FDA, Diarrhea, HBM, Hair loss, Merck, CTLA4, Immune system, Pharmaceutical industry

NEW YORK, Jan. 25, 2024 /PRNewswire/ -- The CTLA4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market is estimated to grow by USD 2.23 billion from  2023 to 2028, growing at a CAGR of 15.11%. High target affinity and specificity of CTLA4 inhibitors are notably driving the growth. Despite several approved therapies, the treatment landscape for advanced or recurrent cancer lacks sufficient drug responsiveness. Available therapies often lead to severe side effects, reducing patient compliance. Chemotherapy, the current standard of care for advanced cancers, causes significant adverse effects like bone marrow suppression, diarrhea, and hair loss. Similarly, surgery and radiation therapy have limitations in treating recurring carcinomas like melanomas. Furthermore, CTLA4 inhibitors work by enhancing the immune system, resulting in comparatively fewer associated side effects than traditional oncology treatments.

Key Points: 
  • High target affinity and specificity of CTLA4 inhibitors are notably driving the growth.
  • Furthermore, CTLA4 inhibitors work by enhancing the immune system, resulting in comparatively fewer associated side effects than traditional oncology treatments.
  • The global proteasome inhibitors market size is estimated to grow by USD 2.91 billion at a CAGR of 7.48% between 2023 and 2028.
  • The HDAC (histone deacetylase) inhibitors market is estimated to grow at a CAGR of 7.73% between 2022 and 2027.

Hair Transplant Market Size to Grow USD 4136.6 Million by 2029 at a CAGR of 3.6% | Valuates Reports

Retrieved on: 
Thursday, January 18, 2024
Woman, Beauty, Growth, Incidence, Medical tourism, Genetics, FUT, USD, FUE, Follicular unit transplantation, Follicular unit extraction, Hair loss, Public opinion, Category, Ageing, Education, Prevalence, Dentistry

The Global Hair Transplant Market size is expected to reach USD 4136.6 Million by 2029, growing at a CAGR of 3.6% from 2023 to 2029.

Key Points: 
  • The Global Hair Transplant Market size is expected to reach USD 4136.6 Million by 2029, growing at a CAGR of 3.6% from 2023 to 2029.
  • The market for hair transplants is growing as a result of shifting cosmetic tastes and changing standards of beauty.
  • Prolonged technological developments in hair restoration methods have been a major factor in the market expansion for hair transplants.
  • The market is expanding as a result of easier access to hair transplant therapies and the rise in medical tourism.

Hair Transplant Market Size to Grow USD 4136.6 Million by 2029 at a CAGR of 3.6% | Valuates Reports

Retrieved on: 
Thursday, January 18, 2024
Woman, Beauty, Growth, Incidence, Medical tourism, Genetics, FUT, USD, FUE, Follicular unit transplantation, Follicular unit extraction, Hair loss, Public opinion, Category, Ageing, Education, Prevalence, Dentistry

The Global Hair Transplant Market size is expected to reach USD 4136.6 Million by 2029, growing at a CAGR of 3.6% from 2023 to 2029.

Key Points: 
  • The Global Hair Transplant Market size is expected to reach USD 4136.6 Million by 2029, growing at a CAGR of 3.6% from 2023 to 2029.
  • The market for hair transplants is growing as a result of shifting cosmetic tastes and changing standards of beauty.
  • Prolonged technological developments in hair restoration methods have been a major factor in the market expansion for hair transplants.
  • The market is expanding as a result of easier access to hair transplant therapies and the rise in medical tourism.

Dignitana signs OncoMedical for distribution in Switzerland and Liechtenstein

Retrieved on: 
Monday, January 15, 2024
National Comprehensive Cancer Network, Patient, Prostate cancer, Health, Attention, Palliative care, Cancer Australia, Breast cancer, ESMO, Cancer, Scalp, Quality of life, NCCN, FDA, Hair loss, Breast, Prostate, Oncology

LUND, Sweden, Jan. 15, 2024 /PRNewswire/ -- Scalp cooling innovator Dignitana AB has signed OncoMedical AG as the exclusive distributor for The DigniCap Scalp Cooling System in Switzerland and Liechtenstein.

Key Points: 
  • LUND, Sweden, Jan. 15, 2024 /PRNewswire/ -- Scalp cooling innovator Dignitana AB has signed OncoMedical AG as the exclusive distributor for The DigniCap Scalp Cooling System in Switzerland and Liechtenstein.
  • Switzerland is a strong market for scalp cooling with many options for quality private healthcare in addition to the public sector clinics.
  • The distribution agreement with OncoMedical seeks to expand that footprint in Switzerland and Liechtenstein, while also upgrading current Dignitana customers to the advanced technology offered by the next generation DigniCap Delta system.
  • "OncoMedical shares our commitment to excellence in technology, customer service and patient care," said Catarina Löwenadler, CEO of Dignitana.

Hims & Hers Teams with Hartford HealthCare to Connect People to In-person Care

Retrieved on: 
Thursday, January 11, 2024
Health, Hospitals, Telemedicine, Virtual Medicine, Practice Management, Health Insurance, Managed Care, Carbon, Diabetes, Dermatology, Patient, ChristianaCare, Weight loss, Multimedia, Mount Sinai Health System, Partnership, Culture, Mental health, Carbon Health, Ochsner Health System, Hers, Hair loss, HHC, Transformation, Hospital

Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, and Connecticut’s most transformative health system, Hartford HealthCare (HHC), today announced a strategic partnership that broadens access to in-person healthcare services.

Key Points: 
  • Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, and Connecticut’s most transformative health system, Hartford HealthCare (HHC), today announced a strategic partnership that broadens access to in-person healthcare services.
  • View the full release here: https://www.businesswire.com/news/home/20240111662974/en/
    The collaboration provides patients with an enhanced and connected healthcare experience when they need care outside the Hims & Hers platform.
  • This initiative reinforces Hims & Hers' mission to expand access to high-quality, affordable and convenient care by integrating an esteemed Connecticut-based healthcare system into its growing network of provider relationships.
  • HHC is known for many of its specialist care services, including for treatment of cardiovascular health, diabetes and prostate care.

Tayloáni, Curls Dynasty, and Fitglow Beauty Are Winners for Most Innovative Products 2024

Retrieved on: 
Thursday, January 11, 2024
Woman, Mother, Science, Calcium, Pollution, Mineral, Pregnancy, Hair loss, Nature, Antioxidant, Cosmetics

NEW YORK, Jan. 11, 2024 /PRNewswire/ -- Taylonáni: Discover the science of hair transformation

Key Points: 
  • Tayloáni presents an elegant thinning hair care line of products uniquely designed for pregnant women and new mothers.
  • Excited and passionate to share her discoveries, Curls Dynasty was born, offering natural products for natural hair.
  • Fitglow Beauty developed by Anna Domi, emerged after she found out that her own skin was sensitive to harsh synthetic products.
  • Skin and Beauty Journal is a digital publication serving an audience located primarily in the United States.

Novel Technology Transforms Baldness Treatment Using Beard and Body Hair

Retrieved on: 
Monday, January 8, 2024
Scalp, BHT, Division, Transplant, FUE, Hair loss, Harbor–UCLA Medical Center, Surgeon, Skin, Eyebrow, Specialization, Eyelash, Patient, Wound healing, Cosmetics

LOS ANGELES, Jan. 8, 2024 /PRNewswire/ -- The ongoing puzzle of having lots of body hair but little on the scalp has confounded many dealing with hair loss.

Key Points: 
  • LOS ANGELES, Jan. 8, 2024 /PRNewswire/ -- The ongoing puzzle of having lots of body hair but little on the scalp has confounded many dealing with hair loss.
  • A breakthrough emerges with Dr. U Hair and Skin Clinic reports a pioneering study published in the esteemed Dermatologic Surgery journal titled ' Beard and Body Hair Transplantation by Follicular Unit Excision Using a Skin-Responsive Device .'
  • This publication introduces the revolutionary UGraft Zeus®, a novel skin-responsive device empowering doctors to seamlessly relocate beard and body hair to bald areas on the scalp through a procedure known as body hair transplantation (BHT).
  • Specialized transplants like eyebrows, beards, and eyelashes achieve more natural aesthetic results by utilizing matched body hair characteristics compared to thick but unmatched scalp hair.